PMVP compared with AVIR: revenue, margins and what each company keeps, and the suppliers and customers both name

PMVPPMV Pharmaceuticals, Inc.

Mkt capRevenueRevenue

AVIRAtea Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

PMVPPMV Pharmaceuticals, Inc.

AVIRAtea Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PMVP1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▲+3.70%—

AVIR

1 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±11.0%▲+0.20%×0.02

May 13 '26±12.9%▼−16.91%×1.31

= impliedPMVP realized, solidAVIR realized, hatchedOne scale, both sides: full bar = 25%× = |realized| ÷ impliedSource: market data

Q1 FY26

±18.1%

▲+11.13%

×0.61

Jan 8 '26±24.5%▲+3.74%×0.15

PMVPPMV Pharmaceuticals, Inc.

1.26▼−1.18%· post 1.26

Mkt cap$67.4M

AVIRAtea Pharmaceuticals, Inc.

4.30▲+1.90%· post 4.30

ClosedNov 6 '26

Mkt cap$345.7M

Compare

ClosedNov 6 '26

PMVPPMV Pharmaceuticals, Inc.

AVIRAtea Pharmaceuticals, Inc.

1.26▼−1.18%post 1.26

Price

4.30▲+1.90%post 4.30

$67.4M

Mkt cap

$345.7M

PMVP1.26▼−1.18%vsAVIR4.30▲+1.90%ClosedNov 6 '26